Ranbaxy’s Troubles Continue – WHO Plans “Extra-ordinary” Action To Confirm Safety Of Prequalified Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The cascading effect of U.S. FDA's enforcement action against India's largest drug maker Ranbaxy has reached the World Health Organization. On its website, WHO has observed that several inspections of Ranbaxy's Paonta Sahib site - most recently in June 2008 - revealed noncompliance with WHO good manufacturing practices standards
You may also be interested in...
Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from U.S. FDA's Import Alert
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).